Another new partnership in Eisai's quest to conquer Alzheimer's

9 May 2019

Japanese firms Eisai (TYO: 4523) and Allm have agreed terms for a capital and business alliance agreement related to ICT digital health solutions and regional medical treatment and care.

The firms will work together on information provision to patients and healthcare professionals, and develop digital health solutions using Allm's ICT systems.

The collaboration aims to leverage Allm's experience in medical ICT systems to help build a "Dementia Ecosystem,” using cutting-edge concepts such as the “Internet of Things,” big data and artificial intelligence.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK